SOLU-CORTEF (hydrocortisone sodium succinate) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. First approved in 1955.
Drug data last refreshed 23h ago · AI intelligence enriched 1mo ago
SOLU-CORTEF is an injectable glucocorticoid (hydrocortisone sodium succinate) approved in 1955 for rapid-onset anti-inflammatory and immunosuppressive therapy. It is administered intravenously or intramuscularly to deliver high blood levels of hydrocortisone quickly, with effects evident within one hour and excretion nearly complete within 12 hours. The drug is used across multiple organ system disorders requiring acute corticosteroid replacement or anti-inflammatory intervention.
With LOE approaching and modest Part D claims (~9,500 annually), the brand team is likely focused on defending market share against generic competition rather than growth initiatives.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SOLU-CORTEF at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on SOLU-CORTEF offers limited career upside given its mature, off-patent status and approaching LOE; roles are primarily defensive and focused on formulary retention and cost management. This product is better suited for professionals seeking stability in hospital-based sales or access roles rather than growth or innovation-driven career trajectories.